Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
EPKINLY(epcoritamab-bysp)治疗大B细胞淋巴瘤重要安全信息-上市-医保-临床适应症-香港济民药业
CD3xCD20双特异性抗体epcoritamab治疗大B细胞淋巴瘤在美欧提交申请-上市-医保-临床适应症-香港济民药业
Lymphoma Australia Epcoritamab - New Treatment for DLBCL
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging ...
Epcoritamab (GEN3013) | Anti-CD3/CD20 Antibody | MedChemExpress
Epcoritamab (Epkinly) - NCBI Bookshelf
Epcoritamab monotherapy in patients with relapsed or refractory ...
Dose escalation of subcutaneous epcoritamab in patients with relapsed ...
epcoritamab-epcoritamab中文说明书,价格,哪里有卖-香港济民药业
Epcoritamab Combination Receives FDA Approval for Relapsed, Refractory ...
Epcoritamab Combination Sets New Standard in Second-Line Follicular ...
New Epcoritamab Data Show Strong Results in B-Cell Lymphomas
FDA Approves Epcoritamab for Treatment of Relapsed, Refractory ...
Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic ...
2024年6月26日FDA加速批准CD3/CD20双特异性抗体疗法Epcoritamab-bysp(艾可瑞妥单抗、Epkinly)用于治疗复发 ...
FDA Approves Epcoritamab-bysp for Relapsed, Refractory Diffuse Large B ...
Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed ...
CD3/CD20 (Epcoritamab) Antibody - Azide and BSA Free (NBP3-44563 ...
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2 ...
Epkinly (epcoritamab) dosing, indications, interactions, adverse ...
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow ...
RxTROSPECT — FDA Approve EPKINLY™ (epcoritamab-bysp) as the First ...
The wonders of the T-cell: bispecific antibodies in diffuse large B ...
FDA Grants Breakthrough Therapy Designation to Epcoritamab for ...
Epcoritamab Approved by FDA to Treat R/R DLBCL
Epcoritamab in Follicular Lymphoma: Method May Reduce CRS, ICANS ...
Anti-CD20/CD3-Epcoritamab Antibody, 68185-H001 | Sino Biological
Epcoritamab-bysp Yields Long-Term Disease Remission in Patients with ...
Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in ...
EHA 2023: Epcoritamab + R2 bei refraktärem/rezidiviertem follikulärem ...
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response ...
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in ...
Epcoritamab Shows Promise In Richter Transformation - EMJ
Epcoritamab Gets Label Expansion for Difficult-to-Treat R/R Follicular ...
The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From ...
Epkinly (Epcoritamab) Approved as First Bispecific Antibody for Most ...
CD3xCD20双特异性抗体epcoritamab治疗大B细胞淋巴瘤患者中，展现出疗效和持久缓解-上市-医保-临床适应症-香港济民药业
Combination of High-Resolution Structures for the B Cell Receptor and ...
T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update
Characterization of a Novel Bispecific Antibody That Activates T Cells ...
Bispecific antibodies in follicular lymphoma | Haematologica
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B ...
Molecular assessment of intratumoral immune cell subsets and potential ...
Frontiers | IgG-like Bispecific Antibody CD3×EpCAM Generated by Split ...
Epcoritamab (CD3E;MS4A1/CD20) Antibody, Monoclonal - Cat. No.10-978 ...
MSK ASH 2023 Insights: Promising Results for Bispecific Antibodies as ...
Epcoritamab: Uses, Dosage, Side Effects, Warnings - Drugs.com
Full article: Epcoritamab in B-cell malignancies: current status and ...
Mechanism of Action - EPKINLY® (epcoritamab-bysp) HCP
Epcoritamab (TEPKINLY®) [Acthera]
Thuốc Epcoritamab điều trị u lympho tế bào B và u lympho nang
Epcoritamab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
FDA Approves Epcoritamab for r/r B-Cell Lymphoma
Intratumoral T-cell composition predicts epcoritamab-based treatment ...
EPKINLY® (epcoritamab-bysp) for 3L+ Diffuse Large B-cell Lymphoma ...
记住所有FDA生物药 | 靶向CD20 x CD3双抗 | Epcoritamab | 弥漫性大B细胞淋巴瘤(DLBCL) - 知乎
FDA批准第2款CD3/CD20双抗：艾伯维/Genmab的Epcoritamab Armstrong 2023年5月19日，艾伯维 ...
Epcoritamab induces potent anti-tumor activity against malignant B ...
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is ...
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific ...
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed ...
Epcoritamab Granted Priority Review for Relapsed/Refractory Large B ...
Epcoritamab (Epkinly), a novel bispecific antibody to target cancer ...
Epcoritamab - Wikipedia, la enciclopedia libre
Epcoritamab Bispecific antibody for large B-cell lymphoma Stock Photo ...
BioCentury - Epcoritamab shows best-in-class potential for DLBCL
SUBCUTANEOUS EPCORITAMAB (GEN3013; CD3XCD20) IN PATIENTS WITH.... EHA ...
$康诺亚-B(02162)$ 创新药周报20230521：Epcoritamab获批，关注CD3×CD20双抗进展原创 ... - 雪球
(PDF) Epcoritamab induces potent anti-tumor activity against malignant ...
Epcoritamab improves outcomes in advanced lymphoma
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab ...
艾可瑞妥单抗(Epcoritamab) - 药物靶点：CD20 x CD3_在研适应症：大B细胞淋巴瘤，复发性 3b 级滤泡性淋巴瘤，纵隔大b ...
Epkinly (Epcoritamab) how to use: Uses, Dosage, Side Effects ...
Full article: Combinability of epcoritamab CD20-targeting T-cell ...
Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic ...
Lower T-cell activation by epcoritamab in presence of tumor cells with ...
Epcoritamab receives FDA approval for patients with R/R DLBCL and HGBCL ...
FDA approves epcoritamab for the treatment of R/R diffuse large B-cell ...
Slide 4/24 at 01:23: Epcoritamab
艾伯维CD3/CD20双抗Epcoritamab在美获批滤泡性淋巴瘤适应症
FL Dosing & Administration - EPKINLY® (epcoritamab-bysp) HCP
Epcoritamab有效率88%，双抗治疗肿瘤时代或将到来 - 知乎
00166-2/asset/f06addfc-255a-4efd-a6c0-73112b12fb49/main.assets/gr1_lrg.jpg)
00166-2/asset/88c3f9b1-701a-4f69-82d7-0f3cc7565fb8/main.assets/gr3_lrg.jpg)
00889-8/asset/f8ef32d8-e2f9-4baf-b793-4a1ee10fea30/main.assets/gr2_lrg.jpg)
.png?format=1000w)
